These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 16204714)

  • 1. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis.
    Farsad M; Schiavina R; Castellucci P; Nanni C; Corti B; Martorana G; Canini R; Grigioni W; Boschi S; Marengo M; Pettinato C; Salizzoni E; Monetti N; Franchi R; Fanti S
    J Nucl Med; 2005 Oct; 46(10):1642-9. PubMed ID: 16204714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer.
    Tuncel M; Souvatzoglou M; Herrmann K; Stollfuss J; Schuster T; Weirich G; Wester HJ; Schwaiger M; Krause BJ
    Nucl Med Biol; 2008 Aug; 35(6):689-95. PubMed ID: 18678354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-11 choline PET/CT imaging for differentiating malignant from benign prostate lesions.
    Li X; Liu Q; Wang M; Jin X; Liu Q; Yao S; Liu S; Li J
    Clin Nucl Med; 2008 Oct; 33(10):671-6. PubMed ID: 18806565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of step-section histopathology to evaluate 18F-fluorocholine PET sextant localization of prostate cancer.
    Kwee SA; Thibault GP; Stack RS; Coel MN; Furusato B; Sesterhenn IA
    Mol Imaging; 2008; 7(1):12-20. PubMed ID: 18384719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT.
    Testa C; Schiavina R; Lodi R; Salizzoni E; Corti B; Farsad M; Kurhanewicz J; Manferrari F; Brunocilla E; Tonon C; Monetti N; Castellucci P; Fanti S; Coe M; Grigioni WF; Martorana G; Canini R; Barbiroli B
    Radiology; 2007 Sep; 244(3):797-806. PubMed ID: 17652190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy.
    Martorana G; Schiavina R; Corti B; Farsad M; Salizzoni E; Brunocilla E; Bertaccini A; Manferrari F; Castellucci P; Fanti S; Canini R; Grigioni WF; D'Errico Grigioni A
    J Urol; 2006 Sep; 176(3):954-60; discussion 960. PubMed ID: 16890665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
    Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R
    Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer.
    Anjos DA; Etchebehere EC; Ramos CD; Santos AO; Albertotti C; Camargo EE
    J Nucl Med; 2007 May; 48(5):764-70. PubMed ID: 17475965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases.
    Budiharto T; Joniau S; Lerut E; Van den Bergh L; Mottaghy F; Deroose CM; Oyen R; Ameye F; Bogaerts K; Haustermans K; Van Poppel H
    Eur Urol; 2011 Jul; 60(1):125-30. PubMed ID: 21292388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. F-18 FDG PET/CT in the management of thyroid cancer.
    Iagaru A; Kalinyak JE; McDougall IR
    Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
    Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
    J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.
    Imani F; Agopian VG; Auerbach MS; Walter MA; Imani F; Benz MR; Dumont RA; Lai CK; Czernin JG; Yeh MW
    J Nucl Med; 2009 Apr; 50(4):513-9. PubMed ID: 19289420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET/CT and choline: diagnosis and staging.
    Farsad M; Schwarzenböck S; Krause BJ
    Q J Nucl Med Mol Imaging; 2012 Aug; 56(4):343-53. PubMed ID: 23013664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor volume assessment by 18F-FDG PET/CT in patients with oral cavity cancer with dental artifacts on CT or MR images.
    Baek CH; Chung MK; Son YI; Choi JY; Kim HJ; Yim YJ; Ko YH; Choi J; Cho JK; Jeong HS
    J Nucl Med; 2008 Sep; 49(9):1422-8. PubMed ID: 18703597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative detection of prostate cancer: a comparison with 11C-choline PET, 18F-fluorodeoxyglucose PET and MR imaging.
    Watanabe H; Kanematsu M; Kondo H; Kako N; Yamamoto N; Yamada T; Goshima S; Hoshi H; Bae KT
    J Magn Reson Imaging; 2010 May; 31(5):1151-6. PubMed ID: 20432351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of whole-body PET/CT, dedicated high-resolution head and neck PET/CT, and contrast-enhanced CT in preoperative staging of clinically M0 squamous cell carcinoma of the head and neck.
    Rodrigues RS; Bozza FA; Christian PE; Hoffman JM; Butterfield RI; Christensen CR; Heilbrun M; Wiggins RH; Hunt JP; Bentz BG; Hitchcock YJ; Morton KA
    J Nucl Med; 2009 Aug; 50(8):1205-13. PubMed ID: 19617339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
    Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
    Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
    Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
    J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings.
    Picchio M; Treiber U; Beer AJ; Metz S; Bössner P; van Randenborgh H; Paul R; Weirich G; Souvatzoglou M; Hartung R; Schwaiger M; Piert M
    J Nucl Med; 2006 Jun; 47(6):938-44. PubMed ID: 16741302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.